Copyright
©2014 Baishideng Publishing Group Inc.
World J Methodol. Sep 26, 2014; 4(3): 163-188
Published online Sep 26, 2014. doi: 10.5662/wjm.v4.i3.163
Published online Sep 26, 2014. doi: 10.5662/wjm.v4.i3.163
Table 4 Examples of orphan-designated drug products with marketing approvals in the United States for both common and rare disease indication
Drug product name | Orphan indications |
Adalimumab | Paediatric Crohn's disease |
Aldesleukin | Primary immunodeficiency disease |
Allopurinol | Ex vivo preservation of kidneys for transplants |
Aminosidine | Tuberculosis and Mycobacterium avium |
Azathioprine | Graft-vs-host disease |
Aztreonam | Improvement of symptoms in bronchiectasis |
Bevacizumab | Ovarian, stomach and pancreatic cancer |
Bleomycin sulphate | Pancreatic cancer |
Cetuximab | Pancreatic cancer |
Cisplatin liposomal | Osteogenic sarcoma metastatic to the lung |
Colchicine | Behcet's Syndrome |
L-Cycloserine | Gaucher's disease |
Cyclosporine | Prophylaxis and treatment of GVH disease |
Cyclosporine A implant | Prevention of rejection in cornea transplant |
Cyclosporine liposomal | Bronchiolitis obliterans |
Doxorubicin | Hepatocellular carcinoma |
Doxorubicin HCl liposomal | Soft tissue sarcomas |
Doxorubicin nanoparticles | Hepatocellular carcinoma |
Eflornithine HCl | Pneumocystis carinii pneumonia in AIDS |
Epoetin alpha | Myelodysplastic syndrome |
Erlotinib HCl | Malignant gliomas |
Etidronate disodium | Degenerative metabolic bone disease |
Everolimus | Gastroenteropancreatic tumors |
Histrelin | Acute intermittent and other porphyries |
Immuneglobulin | Juvenile rheumatoid arthritis |
Infliximab | Chronic sarcoidosis |
Interferon alfa-2a | Esophageal carcinoma |
Peginterferon alfa-2a | Chronic myelogenous leukemia |
Interferon alfa-2b | Ovarian carcinoma, brain tumors |
Peginterferon alfa-2b | Chronic delta hepatitis |
Metronidazole (topical) | Perioral dermatitis |
Metronidazole | Pouchitis |
N-acetylcysteine | Acute liver failure |
Paclitaxel | Pancreatic cancer |
Paclitaxel aqueous gel | Esophageal and brain cancer |
Paclitaxel micellar | Ovarian cancer |
Paclitaxel protein-bound | Stage IIB to IV melanoma |
Sorafenib | Stage IIB through stage IV melanoma |
Ribavirin | Haemorrhagic fever with renal syndrome |
Rituximab | Immune thrombocytopenic purpura |
Thiotepa | Haematopoietic stem cell transplantation |
Tranexamic acid | Hereditary angioneurotic edema |
Urofollitropin | Initiation and re-initiation of spermatogenesis |
Ursodiol | Cystic fibrosis liver disease |
- Citation: Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World J Methodol 2014; 4(3): 163-188
- URL: https://www.wjgnet.com/2222-0682/full/v4/i3/163.htm
- DOI: https://dx.doi.org/10.5662/wjm.v4.i3.163